The first injection of OKT3 in kidney transplant recipients activates the common pathway of coagulation. This may result in early thrombosis of graft vessels. To this day, the cells involved in this phenomenon have not been identified. The aim of this study was to investigate whether circulating monocytes participated in this OKT3-induced coagulopathy. The procoagulant activity (PCA) of circulating monocytes rose from (mean f SEMI 0.15 f 0.02 mU/mL to 0.40 f 0.05 mU/mL at 3 hours (P = .002) and 0.56 f 0.21 at 5 hours (P = .045) after the initial OKT3 injection. These monocytes displayed increased tissue factor expression at the same moments (mean fluorescence intensity: 14 f 2 before OKT3 injection versus 54 f 14 at 3 hours, P = .008 and 34 f 7 at 5 hours, P = .01). Tissue factor mRNA was detected in blood KT3 IS A MURINE IgG2a monoclonal antibody 0 (MoAb) that recognizes the E chain of the CD3-T-cell receptor complex present on mature T lymphocytes.' In vivo injection of OKT3 is known to prevent and treat effectively acute rejection episode^.'.^ However, the first administration of OKT3 triggers a transient, polyclonal activation of T cells. This results in a systemic release of cytokines responsible for flulike symptoms and occasional more serious side effects.',"' In addition, we and others have observed that the first OKT3 injection results in a systemic activation of blood coagulation, as indicated by increased plasma levels of prothrombin fragment 1.2. This procoagulant effect is of clinical importance, as we observed an increased incidence of irreversible intragraft thrombosis after injection of OKT3 in kidney transplant recipients.'~' Previous in vitro experiments have shown that OKT3 was able to induce membrane expression of the tissue factor (TF) molecule on both monocytes and endothelial cells. Endothelial TF expression appears to be mainly triggered by tumor necrosis factor-a (TNF-a), a cytokine produced in large amounts after OKT3 injection.' The mechanisms leading to increased monocyte TF expression after OKT3 challenge in vitro are not as well defined. Although T-cell-derived soluble factors are probably involved,"'^' signals mediated by adhesion molecules could also contribute to increased TF expression. Indeed, cross-linking of CD1 lb/CD18 on monocytes results in marked enhancement of TF activity." Once expressed, TF will bind factor VIINIIa and initiate coagulation through the extrinsic pathway.".I4 Although these in vitro experiments indicate that both monocytes and endothelial cells are able to express tissue factor in response to OKT3, the role of these cells in the systemic activation of coagulation triggered by OKT3 in vivo remains unknown. The first aim of the present study was to investigate whether the initial injection of OKT3 triggered TF expression and activity on circulating monocytes in vivo. Secondly, we measured the expression of several adhesion molecules on the monocyte membrane. Finally, we investigated whether nonmitogenic anti-CD3 antibodies induced monocyte procoagulant activity in vitro, despite their inability to trigger cytokine release.
by reverse transcriptase-polymerase chain reaction as early as 2 hours after OKT3 administration. The circulating monocytes also displayed a steady increase in membrane expression upregulation of ICAM-1, CD29, CDllb, and CDllc. In vitro experiments showed that OKT3 as well as 2 mitogenic, humanized anti-CD3 antibodies potently induced monocytic PCA whereas the 4 nonmitogenic anti-CD3 antibodies tested were over 1,000-fold less potent than OKT3. We conclude that (1) OKT3 induces in vivo tissue factor gene upregulation and membrane expression resulting in increased PCA of circulating monocytes; and (2) nonmitogenic anti-CD3 antibodies seem devoid of significant procoagulant properties. 0 1996 by The American Society of Hematology.
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Although these in vitro experiments indicate that both monocytes and endothelial cells are able to express tissue factor in response to OKT3, the role of these cells in the systemic activation of coagulation triggered by OKT3 in vivo remains unknown. The first aim of the present study was to investigate whether the initial injection of OKT3 triggered TF expression and activity on circulating monocytes in vivo. Secondly, we measured the expression of several adhesion molecules on the monocyte membrane. Finally, we investigated whether nonmitogenic anti-CD3 antibodies induced monocyte procoagulant activity in vitro, despite their inability to trigger cytokine release.
MATERIALS AND METHODS

Blood collection and cell isolation in kidney transplant recipients.
All patients were kidney transplant recipients who were studied on the day of surgery. OKT3 (5 mg intravenous [IV]) was administered after induction of narcosis. The moment of OKT3 injection was defined as T = 0. Associated medications were azathioprine (2 mg/ kg) and methylprednisolone (8 mgkg 1V) administered 2 to 4 hours before surgery. Control patients received cyclosporine A (6 mgkg before surgery) instead of OKT3. In these patients, T = 0 was defined as the time after induction of narcosis.
Blood samples were collected through a central venous catheter immediately before (T = 0) and 3, 5, 8, 16, and 24 hours after the first injection of OKT3. In control patients, blood sampling was perfonned with the same timing. After discarding the first 10 mL, 24 mL of blood was collected into vacutainer tubes containing EDTA as the anticoagulant (Venoject; T e n " Europe, Leuven, Belgium Ex vivo cytojluorometer analysis of TF and adhesion molecule expression on monocytes. PBMC (50 pL of the cell suspension adjusted to IO6 monocytes/ml) were coincubated for 30 minutes at 37°C with anti-CD14-PE (Leu M3-PE; Becton Dickinson, San Jose, CA) and fluoresceinated MoAbs specific for either: (1) TF (4508 CJ murine IgGl MoAb; American Diagnostica, Greenwich, CT); (2) CD29, the /3l subunit of the VLA integrin family (BD-15, murine IgGl; Serotec, Oxford, UK); (3) CDllb, the a 2 subunit of the /32 integrin family (44, murine IgG1; Serotec); (4) CDllc, the a 3 subunit of the p2 integrin family (3.9, murine IgGl; Serotec); or (5) CD54-ICAM-1, a member of the Ig superfamily (84H10, murine IgGl; Immunotech, Marseille, France). Control staining for TF and adhesion molecules was performed with a pool of nonrelevant fluorescein isothiocyanate (FITC)-labeled murine IgGl (Serotec and Immunotech). After washing with PBS supplemented with 0.02 m o l / L sodium azide, the cells were resuspended in PBS medium containing 5 pg/mL 7-AAD (7-aminoactinomycin D; Molecular Probes Inc, Eugene, OR). The labeled cells were analyzed by flow cytometry on a FACScan (Becton Dickinson, Mountain View, CA). Lack of 7-AAD staining ensured that only viable cells were analyzed. Monocytes were gated by both side-and forward-scatter properties as well as high expression of CD14. At least 1,500 events that fulfilled these conditions were analyzed for FITC staining. Before each experiment, the FACScan was calibrated using the Calibrite kit (Becton Dickinson).
In vivo detection of whole-blood tissue factor mRNA after OKT3 injection. TF mRNA accumulation in whole-blood cells was analyzed for each sample. One milliliter of whole blood was added to 9 mL of surfactant (Catrimox 14; IBC, Oakdale, IA) to lyse cells and then centrifuged at 9,OOOg for 20 minutes. The pellet was dissolved and the mRNA content was extracted using the guanidinium thiocyanate method, reversed transcribed in cDNA and amplified by polymerase chain reaction (FCR) as previously described.16
Effects of mitogenic and nonmitogenic anti-CD3 MoAbs on in vitro procoagulant activity of normul PBMC. PBMC from healthy volunteers were isolated from blood anticoagulated with citrate phosphate dextrose adenine (CPDA). After centrifugation of buffy coats on a Ficoll-Hypaque gradient and extensive washing with calcium and magnesium-free Hanks' balanced salt solution (HBSS), the cells were adjusted to 5 X lo5 monocytedml. Final PBMC preparations contained 17% to 33% monocytes with a lymphocyte-to-monocyte ratio >3:1. Incubation with the anti-CD3 MoAbs was performed for 6 hours in RPMI 1640 supplemented with 20 mmoVL HEPES, 1% glutamine, and 10% LPS-free fetal calf serum (FCS; Myoclone, GIBCO, Paisley, Scotland) at 37°C in air atmosphere supplemented with 5% COz. FCS was decomplemented by heating 30 minutes at 56°C. The following mitogenic MoAbs were assayed (Table 1) Results are shown as mean 2 SEM. Differences between patient groups were evaluated by Student's t-test. For the in vitro evaluation of MoAbs, repeated ANOVA followed if significance (P < .05) by Bonferroni multiple comparisons posttest was performed.
Statistical analysis.
RESULTS
PBMC from kidney transplant recipients display increased tissue factor type PCA ajler the first injection of OKT3. As shown in Fig 1, no significant change in procoagulant activity was observed in circulating PBMC of control patients. By contrast, the first injection of OKT3 resulted in a large increase in PBMC's procoagulant activity, which was already manifest at 3 hours, reached a maximum around 5 hours and then slowly decreased. Procoagulant activity was still slightly above control values at 24 hours, but no further increase was seen after the second OKT3 injection (data not shown). The increased procoagulant activity was caused by TF, as indicated by the inhibitory effect of the anti-factor VI1 MoAb added to the normal plasma used in the clotting assay (Table 2) .
Increased expression of membrane tissue factor on circulating monocytes afrer the first injection of OKT3. Figure  2 shows a fluorocytometric analysis of TF expression on monocytes identified by physical characteristics as well as CD14 staining. Only background staining was observed before OKT3 injection. A slight increase in fluorescence was observed when monocytes obtained 3 hours after OKT3 injection were incubated with the control MoAbs, but the mean fluorescence intensity remained far below the one recorded after staining with the anti-TF MoAb (Fig 2) . Figure 3 shows the mean fluorescence intensity for TF on monocytes from OKT3 and control kidney transplant recipients. The expression of TF was markedly increased in OKT3 patients (Fig  3) . The maximum staining was observed at 3 hours, with increased levels still present at 16 hours before returning to near basal values at 24 hours. No increased monocyte TF expression was found after the second OKT3 injection (data not shown).
Detection of tissue factor mRNA in whole blood after OKT3 injection. Reverse PCR experiments indicated that the blood from patients treated with OKT3 contained increased amounts of tissue factor mRNA (Fig 4) . TF mRNA appeared sometime between 1 and 2 hours after OKT3 injec- shown in Fig 5. Except for CD29 that slowly increased after surgery in control patients, no significant changes were observed on circulating monocytes isolated from patients treated with cyclosporin A. However, OKT3 led to marked enhancement of these four adhesion molecules. Near-maximal levels of ICAM-I, CDI Ib, and CDI I C were already present at 3 hours. CDI I C expression decreased rapidly thereafter, whereas ICAM-I and CDI Ib showed sustained expression for at least 8 hours. Different kinetics occurred for CD29 expression, which steadily increased during 16 hours. The background staining of monocytes observed after incubation with control MoAbs increased moderately after OKT3 injection but remained far below the adhesion molecule staining.
Induction ?f procoagulant activie on PRMC by mitogenic and nonmirogenic soluhle anti-CD3 MoAhs. The observation that monocytes displayed strong tissue factor activity in vivo as they did in vitro after OKT3 stimulation suggested that in vitro assays of monocyte procoagulant activity could help predict the in vivo procoagulant properties of other antLCD3 antibodies. As previously shown," incubation of PBMC with soluble OKT3 resulted in a dose-dependent increase in procoagulant activity (Fig 6) . Significant effects were already visible with 0.1 ng/mL of OKT3, and plateau levels were reached with 10 ng/mL. The two mitogenic, OKT3-CDR-grafted, humanized MoAbs (209 IgG 1 and 209 IgG4) also triggered large increases in procoagulant activity. Although they seemed somewhat less potent on a molar basis than OKT3, the maximum levels seen at 1,000 ng/mL were equivalent to those observed with OKT3. On the opposite, the nonmitogenic anti-CD3 MoAbs, whether of human or murine origin, induced only modest increases in procoagulant activity, and were at least 1,000-fold less potent than OKT3 on a molar basis. Table 1 for description of the MoAbsl. After 6 hours of incubation the PBMC procoagulant activity was assessed in a one-stage clotting assay. Values are mean ? SEM of four different experiments with duplicate cultures. *, P < .05; **, P < .01.
ICAM-
DISCUSSION
The main conclusion of this study is that in vivo, the first injection of the OKT3 MoAb leads to a large increase in procoagulant activity on circulating monocytes. Although our study does not exclude a possible role for endothelial cells, it should be pointed out that the kinetics of blood coagulation activation closely parallel the expression of tissue factor on monocytes.
In the setting of OKT3 injection, TF was responsible for most, if not all. of the enhanced monocytic procoagulant activity since it could be prevented by factor VI1 neutralization present in the one-stage clotting assay. Reverse PCR experiments indicated that the increased tissue factoractivity was associated with accumulation of TF mRNA. Although mRNA was isolated from whole blood, it is likely that TF mRNA came from monocytes as they seem to be the only circulating cell able to express this gene." Kinetic experiments showed that TF mRNA appeared first with a maximum at 2 hours, followed by the expression of monocytic membrane tissue factor 1 hour later, at the same time as the maximal procoagulant activity of PBMC. Thrombin generation rapidly followed, as indicated by increased levels of prothrombin fragment 1.2, which reached a maximum 4 hours after OKT3 injection?
Induction of tissue factor after OKT3 injection occurred in the context of generalized monocyte activation, as shown by the increased expression density of several adhesion molecules on circulating monocytes. Along this line, injection of a mitogenic anti-CD3 MoAb in mice resulted in activation of splenic macrophages, as these cells displayed increased amounts of messenger RNA for both interleukin-1 and interleukin-6.20 Increased expression of monocytic adhesion molecules might have two important consequences regarding OKT3 coagulopathy. First, it could explain the increased susceptibility of graft vessels to thrombotic events. Indeed, the cold ischemia associated with kidney graft preservation also results in upregulation of adhesion molecules on endothelial cells," so that activated monocytes are likely to localize preferentially to the graft endothelium leading to in situ thrombosis. Second, signaling through adhesion molecules is known to further enhance monocyte tissue factor activity (see below).
It is now admitted that the acute events triggered by OKT3 in vivo are similar to those elicited by endotoxin. Indeed, proinflammatory cytokines are released in comparable amounts and Furthermore, injection of LPS in human volunteers also results in the activation of the coagulation's extrinsic pathway, again with kinetics comparable to those observed after OKT3 injection. Although some of the molecular mechanisms underlying LPS-and OKT3-induced monocyte activation probably differ, our findings in OKT3 patients suggest that the study of monocytes in septic patients is worth investigating.
Although the present study was not designed to investigate the mechanisms responsible for tissue factor expression on monocytes after OKT3 injection, data from other experimental systems indicate that T-cell-derived cytokines like TNFa, interferon-y, or other mediators such as macrophage-procoagulant inducing factor, could be in~olved.'~.~~ In addition, cross-linking of CDl lb/CD18, a process that also upregulates TF activity,12 could take place after OKT3 injection. Indeed, the complement system is activated and C3bi is produced.26 This molecule binds to CD1 lb/CD18, so that opsonization by C3bi will result in monocytic CDllWCD18 crosslinking."
The prominent in vivo monocyte activation triggered by OKT3 led us to examine several anti-CD3 MoAbs that could be considered for clinical use for their ability to induce in vitro TF activity on monocytes. Only the MoAbs able to stimulate cytokine release and cell proliferation as a consequence of monocyte Fc receptor binding induced high procoagulant activity of monocytes in vitro. Interestingly, an IgA switch variant of OKT3 that is not mitogenic in vitro, because human monocytes lack Fc receptors for IgA, has recently been injected to patients, with no evidence of coagulation activation.** Thus, our in vitro assay does indeed appear and an anti-T-cell receptor MoAb3' both effectively deplete or modulate circulating CD3+ cells. However, comparative trials will be needed to see if they allow for the same improvement of long-term kidney graft survival as does 0KT3.32
In conclusion, the present work shows that in vivo activation of circulating mononuclear cells during the self-limited septic-like syndrome that follows OKT3 injection results in coordinate expression of tissue factor gene and protein. This phenomenon is likely to have contributed to the thrombosis observed after OKT3 therapy. Nonmitogenic anti-CD3 antibodies appear devoid of significant procoagulant properties, and could become useful therapeutic alternatives to OKT3. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
